Trillium Therapeutics Inc (TRIL)

[Inoviorulez]

Let people be ignorant. Trillium's products TTI-621 and TTI-622 are superior to FTSV's magrolimab. TRIL should be equal in market cap to FTSV right now. Obviously it won't gap that high immediately, but over time it will start to trend and trade up higher until it matches it valuation. The smart people are accumulating now, those types are bashing it.

1,)You have TTI-621 being the only CD47 to generate complete responses in blood cancer and solid tumors at doses completely lower, not done with dose escalation yet, no Maximum tolerated dose being reached

2,)TTI-622 put up same or better response rate numbers as an IgG4 agent like magrolimab , but a 30x lower doses. Magrolimab to give you an idea is at 30 mg/kg, while the reported data for TTI-622 was 0.5 mg/kg. A much lower dose yet put up same or better ORR than magrolimab at 30x higher dose.

TRIL is a pure buy and hold at this point until either

A,) partnership with STING as suggested by company in 1st half of 2020 is obtained

B.) In my opinion will eventually be bought out. Whether its for $2 billion or $3 billion it will be bought out. Why? CD47 blocks the "eat me" signal on cancer cells letting macrophages (the main immune system)swallow cancer cells. It is the next generation in checkpoint inhibitor therapy like Keytruda and Opdivo. Why would someone sell now at mere pennies, when this is going to be worth billions?

Forgot to add: Trilliums drugs are fusion proteins CD47 and they don't bind to red blood cells which means they don't cause side effects of anemia like magrolimab does. That means TRIl's TTI-621 and TTI-622 are not only better at lower doses compared to FTSV's magrolimab but they are even safer to take.